Excellerate compound profiling for AdoRx Therapeutics supports major collaboration success, in the development of novel therapeutics for the treatment of lung cancer.
AdoRx Therapeutics, a UK-based drug discovery company, announced on 28 February 2019 that it has entered into a strategic collaboration with Johnson & Johnson Innovation LLC and the Lung Cancer Initiative at Johnson & Johnson to develop novel therapeutics for the treatment of lung cancer, based on modulation of the adenosine pathway.
Excellerate Bioscience has worked closely in support of AdoRx compound development programs since 2017, providing in vitro binding and functional pharmacological data to characterise the mode of action and receptor selectivity. Our medium-throughput kinetic binding assay platforms, established for all four adenosine receptor subtypes, assisted in profiling for “fit for purpose” adenosine receptor antagonists designed to overcome the effects of high adenosine levels in the tumour microenvironment.
Professor Steven Charlton commented: “We congratulate AdoRx Therapeutics on their fantastic success in securing this major partnership, and look forward to continuing to work with them closely to facilitate the transition of their exciting compounds into clinical development.”